BioNTech SE

The US Food and Drug Administration’s recent safety labeling changes quantifying the myocarditis risk with COVID-19 mRNA vaccines are unlikely to quell the concerns of Centers for Disease Control and

Moderna appears to have a pathway to approval for its investigational influenza/COVID-19 combination vaccine mRNA-1083 now that it reported positive Phase III efficacy data on June 30 for mRNA-1010, a

BioNTech’s acquisition of fellow German mRNA company CureVac underscored a trend in biotech: many companies form around new technologies, but not all succeed. A Very German Transaction BioNTech’s acq

The promise of mRNA therapeutics has been held back by a fundamental physical limitation: lipid nanoparticles containing mRNA are inherently fragile and prone to aggregation when subjected to the mech